Poster Presentations Session I
Poster Presentations Session I Monday, May 18, 2015
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:15 PM
POSTER AUTHOR DISCUSSION: 1:15 PM - 2:15 PM
POSTERS DISMANTLE: 2:15 PM


Poster display locations are shown below the poster codes
RESEARCH ON METHODS - Clinical Outcomes Methods
PRM1
A1
DEVELOPMENT AND VALIDATION OF A U.S. ADMINISTRATIVE CLAIMS-BASED ALGORITHM TO CLASSIFY PATIENTS WITH TYPE 2 DIABETES MELLITUS INTO RENAL IMPAIRMENT STAGES
Johnston S1, Sheehan J2, Riehle E1, Cappell KA3, Varker H1, Anzalone D4, Ghannam A2, Kalsekar I4
1Truven Health Analytics, Bethesda, MD, USA, 2AstraZeneca, Fort Washington, PA, USA, 3Truven Health Analytics, Ann Arbor, MI, USA, 4AstraZeneca, Wilmington, DE, USA

PRM2
A2
COMPARISON OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION AND CHRONIC CONSTIPATION PATIENT IDENTIFICATION UTILIZING ADMINISTRATIVE CLAIMS-BASED ALGORITHMS, MODIFIED ROME III DIAGNOSTIC CRITERIA, AND PATIENT-REPORTED PHYSICIAN DIAGNOSES
Buono JL1, Stephenson JJ2, Spalding WM3, Cai Q2, Tan H2, Carson RT1, Doshi JA4
1Actavis Inc., Jersey City, NJ, USA, 2HealthCore Inc., Wilmington, DE, USA, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 4University of Pennsylvania, Philadelphia, PA, USA

PRM3
A3
PSYCHOMETRIC VALIDATION OF PERFORMANCE OUTCOMES (PERFOS) FOR USE WITH HIP FRACTURE (HF) POPULATIONS
Gentile B1, Ballinger RS2, Doll HA3, Naegeli A4, Bush EN4
1ICON, San Francisco, CA, USA, 2ICON, Oxford, UK, 3ICON plc, Oxford, UK, 4Eli Lilly, Indianapolis, IN, USA

PRM4
A4
GETTING THE FULL PICTURE: THE IMPORTANCE OF EXRAPOLATING BEYOND THE DATA
Al-Mutairi R, Rittenhouse B
MCPHS University, Boston, MA, USA

PRM5
A5
COMPARING DIAGNOSIS-BASED AND PRESCRIPTION-BASED COMORBIDITY MEASURES FOR PREDICTING HEALTH SERVICE UTILIZATION AND COSTS
Gangan N, Banahan III B
University of Mississippi, University, MS, USA

PRM6
A6
MATCHING-ADJUSTED INDIREC TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC)
Tremblay G1, Holbrook T2, Milligan G3, Pelletier C1
1Eisai, Woodcliff Lake, NJ, USA, 2Adelphi Real World, Manchester, UK, 3Adelphi Real World, Bollington, UK

PRM7
A7
PROSPECTIVE BENEFIT-RISK MONITORING OF NEW DRUGS FOR RAPID ASSESSMENT OF NET FAVORABILITY IN ELECTRONIC HEALTHCARE DATA
Gagne JJ1, Bykov K2, Najafzadeh M1, Choudhry NK1, Martin DP3, Kahler K3, Rogers JR2, Schneeweiss S1
1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRM8
A8
QT PROLONGATION IDENTIFICATION IN RETROSPECTIVE STUDIES
Ye Y, Caffrey AR
University of Rhode Island, Kingston, RI, USA

PRM9
A9
COMPARISON OF BENEFIT-RISK ASSESSMENT METHODS FOR PROSPECTIVE MONITORING OF NEWLY MARKETED DRUGS: A SIMULATION STUDY
Gagne JJ1, Najafzadeh M1, Choudhry NK1, Bykov K2, Kahler K3, Martin DP3, Rogers JR2, Schneeweiss S1
1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRM10
A10
USAGE OF PROPENSITY SCORE, INSTRUMENTAL VARIABLE, OR MACHINE LEARNING FOR REAL WORLD DATA ANALYSIS
Choi S
PAREXEL International, Billerica, MA, USA

PRM11
A11
EVALUATING CONTENT VALIDITY OF PERFORMANCE OUTCOMES (PERFOS): ESTABLISHING THE PATIENT-RELEVANCE OF THREE PERFOS IN ELECTIVE TOTAL HIP REPLACEMENT (ETHR)
Ballinger RS1, Kerr C1, Bush EN2
1ICON, Oxford, UK, 2Eli Lilly, Indianapolis, IN, USA

PRM12
A12
CLINICAL TRIALS REGISTRIES FOR SYSTEMATIC REVIEWS – AN ALTERNATIVE SOURCE FOR UNPUBLISHED DATA
Halfpenny NJ1, Thompson JC2, Quigley JM3, Scott DA3
1ICON Health Economics & Epidemiology, Oxford, UK, 2ICON Health Economics, Oxford, UK, 3ICON Health Economics and Epidemiology, Oxford, UK

PRM13
A13
DATA EXTRACTION FOR SYSTEMATIC REVIEW – WHERE TO LOOK FOR DATA OUTSIDE THE PRIMARY PUBLICATION
Quigley JM1, Halfpenny NJ2, Thompson JC2, Scott DA1
1ICON Health Economics and Epidemiology, Oxford, UK, 2ICON Health Economics, Oxford, UK

PRM14
WITHDRAWN

PRM15
A14
INVESTIGATION OF RELATIONSHIPS BETWEEN BIOMARKERS OF POTENTIAL HARM AND CIGARETTE SMOKING MEASURES AMONG CURRENT, PAST, AND NON-SMOKERS BASED ON NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2007-2012
Saxena K1, Liang Q2, Muhammad-Kah R2, Sarkar M2
1Virginia Commonwealth University, Richmond, VA, USA, 2Altria Client Services Inc, Richmond, VA, USA

PRM16
A15
COMBINING MCDA WITH ADVANCED STATISTICS TO TACKLE CHALLENGES OF DATA AND JUDGMENT UNCERTAINTY: CASE STUDY OF SAFETY ASSESSMENTS
Goetghebeur MM1, Wagner M2, Nikodem M3, Zyla A3, Micaleff A4, Amzal B5
1LASER Analytica & University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3LASER Analytica, Krakow, Poland, 4MerckSerono SA, Eysins, Switzerland, 5LASER Analytica, London, UK

PRM17
A16
LONGITUDINAL AND CROSS SECTIONAL ASSESSMENTS OF HEALTH UTILITY IN ADULTS WITH HIV/AIDS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Tran B
Hanoi Medical University, Hanoi, Vietnam

PRM18
A17
IMPROVING PARAMETER ESTIMATION FOR A DECISION-ANALYTIC MARKOV MODEL TO EVALUATE THE USE OF NOVEL BIOMARKER LED STRATEGIES FOR PREVETION OF CARDIOVASCULAR DISEASE
Lamrock F1, Cairns K1, Kee F1, Conrads-Frank A2, Schnell-Inderst P2, Salomaa V3, Blankenberg S4, Zeller T4, Saarela O5, Kuulasmaa K3, Kühne F2, Siebert U2
1Queen's University Belfast, Belfast, UK, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 3THL - National Institute for Health and Welfare, Helsinki, Finland, 4University Health Center Hamburg, Hamburg, Germany, 5McGill University, Montreal, QC, Canada

PRM19
A18
DO DIFFERENT MODELING TECHNIQUES CHANGE RANKINGS OF HOSPITAL PERFORMANCE? : MULTILEVEL MODELING VS. STANDARD LOGISTIC REGRESSION
Yucel A, Ferries EA, Sharma M, Johnson M, Aparasu R
University of Houston, Houston, TX, USA

PRM20
A19
COMPARING THE PREDICTIVE PERFORMANCE OF TWO VARIANTS OF THE ELIXHAUSER COMORBIDITY MEASURES FOR ALL-CAUSE IN-HOSPITAL MORTALITY IN A LARGE MULTI-PAYER U.S. ADMINISTRATIVE DATABASE
Fortin Y1, Crispo J1, Emons MF2, Mattison DR3, Krewski D1
1University of Ottawa, Ottawa, ON, Canada, 2Cerner Corporation, Culver City, CA, USA, 3Risk Sciences International, Ottawa, ON, Canada

PRM21
A20
STATISTICAL IDENTIFICATION OF PATIENT SELECTION BIAS IN RETROSPECTIVE CHART REVIEWS
Signorovitch JE1, Reichmann WM1, Li N1, Liu Z2, Hao Y2, Perez JR2
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRM22
A21
METASTATIC-FREE SURVIVAL AND OVERALL SURVIVAL IN PROSTATE CANCER
Li T1, Thompson M2, Tran D2
1Janssen Research & Development, Raritan, NJ, USA, 2Cornerstone Research Group, Burlington, ON, Canada

RESEARCH ON METHODS - Cost Methods
PRM23
B1
CONTRASTING COST-EFFECTIVENESS RESULTS DERIVED FROM CONTEMPORARY SETS OF ALTERNATIVE RISK EQUATIONS IN TYPE 2 DIABETES
Foos V1, Lamotte M2, McEwan P3
1IMS Health, Basel, Switzerland, 2IMS Health Consulting, Brussels, Belgium, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM24
B2
COST-BENEFIT ANALYSIS OF WHOLE BODY BONE SCINTIGRAPHY IN THE PRE-TRANSPLANT ASSESSMENT OF ADULT PATIENTS, BEARERS OF HEPATOCELLULAR CARCINOMA, IN A LIVER TRANSPLANT WAITING LIST, FROM DEAD DONORS, IN A REFERENCE HOSPITAL IN THE SOUTH OF BRAZIL
Balbinotto G1, BrandÃo A2, Rodriguez S2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2UFCSPA, PORTO ALEGRE, Brazil

PRM25
B3
COST-UTILITY EVALUATION OF CONTINUING EDUCATION FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS USERS IN PERNAMBUCO – BRAZIL
Aquino CM1, Lima RC2, Bezerra AF2, Sousa IM3, Cesse EÂ3, Carvalho EM2, Fontbonne A4
1Federal University of Pernambuco, Recife, Brazil, 2Federal University of Pernambuco, RECIFE, Brazil, 3Oswaldo Cruz Foundation - Fiocruz, Recife, Brazil, 4Institut de Recherche pour le Développement, Marseille, France

PRM26
B4
MODELS USED IN ECONOMIC ANALYSES OF TICAGRELOR AND PRASUGREL FOR ACUTE CORONARY SYNDROMES: A STRUCTURED REVIEW
Law EH, Sharma D, Pickard S
University of Illinois at Chicago, Chicago, IL, USA

PRM27
B5
REVIEW OF COST-EFFECTIVENESS ANALYSES OF VARICELLA VACCINATION: WHICH MODEL STRUCTURE ASSUMPTIONS AND INPUT PARAMETERS MATTER?
Talbird SE1, Mauskopf JA1, Yang HK2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Merck & Co., Inc., West Point, PA, USA

PRM28
B6
IMPLICATIONS OF THE INTER-RELATEDNESS OF THE PROPORTIONAL AND ABSOLUTE QALY SHORTFALL MEASUREMENTS FOR DISEASE BURDEN
Kusel J1, Beale RC2, Maruszczak M1
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK

PRM29
B7
EXPLORING POTENTIAL DRIVERS OF THE SYSTEMATIC OVERUSE OF HEALTHCARE IN THE UNITED STATES USING THE JOHNS HOPKINS OVERUSE INDEX (JHOI)
Bridges JF1, Zhou M1, Segal J2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins University, Baltimore, MD, USA

PRM30
B8
SHOULD DECISION MAKERS EMBRACE NON-CONSTANT DISCOUNTING?
Paulden M, McCabe C
University of Alberta, Edmonton, AB, Canada

PRM31
B9
EXPLICATIVE MODEL OF THE HEALTH EXPENDITURE FOR CONTRIBUTIVE HEALTH SUBSYSTEM POPULATION IN COLOMBIA
Romero M1, Marrugo R2, Acero G3, Quinche G4, Grosso G5, Moreno Y6, Lee J4, Reinales J4, Vivas D7
1Salutia Foundation, Bogota, Colombia, 2Salutia´s Foundation- Research center in economy, management and health technologies., Bogota, Colombia, 3Salutia Foundation- Research center in economy, management and health technologies., Bogota, Colombia, 4Coomeva Group, Cali, Colombia, 5Group SaludCoop, Bogotá, Colombia, 6Saludcoop group, Bogotá, Colombia, 7universidad Politécnica de Valencia, Valencia, Saipan

PRM32
B10
SUGGESTION OF NEW METHODS TO CALCULATE CONFIDENCE INTERVAL FOR INCREMENTAL COST-EFFECTIVENESS RATIO WHICH SOLVE THE ISSUES WITH CONVENTIONAL METHOD
Aranishi T, Ikeda S
International University of Health and Welfare, Ohtawara City, Japan

PRM33
B11
METHODOLOGY USING PHARMACY AND MEDICAL CLAIMS DATA TO EVALUATE REAL-WORLD OUTCOMES AND COSTS OF IVF TREATMENT IN THE US
Corvino FA1, Surinach A1, Locklear JC2, Howe AM2, Hayward B2, Mahony MC2
1Genesis Research, LLC, Hoboken, NJ, USA, 2EMD Serono, Inc., Rockland, MA, USA

PRM34
B12
A COST ANALYSIS OF KIDNEY THERAPY OPTIONS
Younis M1, Forgione D2, Alkatib A3, Jabr S4, Hartmann M5, Kisa A6
1Jackson State University, New Orleans, LA, USA, 2UTSA, San antonio, Palestine, 3Al-watani Hospital, Ramallah, Palestine, 4Minsitry of Health, Ramullah, Palestine, 5Friedrich Schiller University of Jena, Jena, Germany, 6Zirve University, Gazyianteap, Turkey

PRM35
B13
ASSESSING THE INCREMENTAL PREDICTIVE VALUE OF HEALTHCARE UTILIZATION PATHWAYS IN RISK PREDICTION MODELING
Kuwornu JP1, Lix L1, Quail J2, Wang E2, Osman M2, Teare G2
1University of Manitoba, Winnipeg, MB, Canada, 2Saskatchewan Health Quality Council, Saskatoon, SK, Canada

PRM36
B14
NON-DISCRETIONARY INPUTS ARE IMPORTANT FACTORS IN HOSPITAL EFFICIENCY STUDIES AND POLICY EVALUATION
Pasupathy K, Sir M
Mayo Clinic, Rochester, MN, USA

PRM37
B15
IMPACT OF SINGLE RISK FACTOR CHANGES ON LONG-TERM OUTCOMES AND COST IN A TYPE 2 DIABETES MODELING STUDY CONTRASTING PROJECTIONS WITH UKPDS68, SWEDISH NATIONAL DIABETES REGISTRY AND THE ADVANCE RISK EQUATIONS
McEwan P1, Lamotte M2, Foos V3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2IMS Health Consulting, Brussels, Belgium, 3IMS Health, Basel, Switzerland

PRM38
B16
THE COST OF DRUG-RELATED MORBIDITY THAT LEAD TO EMERGENCY VISITS IN A BRAZILIAN HOSPITAL
Freitas G1, Balbinotto G2, Hughes D3, Heineck I1
1UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil, 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Bangor University, Bangor, UK

RESEARCH ON METHODS - Databases & Management Methods
PRM39
B17
IS THE PREVALENCE OF ALZHEIMER'S DISEASE UNDERESTIMATED? COMPARISONS AND CONTRASTS OF DIFFERENT APPROACHES IN ESTIMATING ALZHEIMER'S DISEASE
Yuan J, Lu K
University of South Carolina, Columbia, SC, USA

PRM40
B18
UNIFIED DATABASE CREATION APPLIED TO PUBLIC BRAZILIAN HEALTH INFORMATION SYSTEMS FROM THE HOSPITAL, OUTPATIENT AND MORTALITY INFORMATION SYSTEMS
Pereira RG1, Leal GS2, Silva LV3, Andrade EI1, Acurcio Fd2, Cherchiglia ML1, Guerra Junior AA2
1Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 3Faculdade Promove, Belo Horizonte, Brazil

PRM41
B19
VALIDITY OF MEDICAID ANALYTIC EXTRACT (MAX)-2009, OUTPATIENT (OT) AND PROVIDER CHARACTERISTICS (PC) DATA FOR USE IN MENTAL HEALTH RESEARCH
Medhekar R, Chen H
University of Houston, Houston, TX, USA

PRM42
WITHDRAWN

PRM43
B20
DEVELOPMENT OF A DATABASE OF PUBLISHED REGULATORY RECOMMENDATIONS CONCERNING THE USE OF CLINICAL OUTCOME ASSESSMENT (COAS) IN DRUG DEVELOPMENT: OUTCOMES INSITE
Perret C1, Roborel de Climens A2
1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France

PRM44
B21
A VIRTUAL DATABASE TO MEASURE COSTS ASSOCIATED WITH COMORBIDITIES AMONG PATIENTS WITH CHRONIC HCV
Kawabata H1, Behl A1, Hines P1, Liu T1, Sill B1, Hede S1, Gorsh B1, Moorthy V2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Mu Sigma, Northbrook, IL, USA

PRM45
C1
BIG DATA IN EMERGENCY DEPARTMENT CARE DELIVERY: BENEFITS OF RADIO FREQUENCY IDENTIFICATION
Benkhadra K, Sir M, Nestler D, Hellmich T, Pasupathy K
Mayo Clinic, Rochester, MN, USA

PRM46
C2
WHY PEER-REVIEW JOURNALS REJECT REAL-WORLD AND HEALTH-ECONOMIC PAPERS
Hartog TE1, Peters K2, Diamond M1, Nuottamo N1
1Excerpta Medica, Amsterdam, The Netherlands, 2Excerpta Medica, London, UK

PRM47
C3
UTILIZING ELECTRONIC MEDICAL RECORD NETWORKS FOR IDENTIFYING PATIENTS FOR CLINICAL TRIAL RECRUITMENT
Spencer J, Wilson A, Bailey N, Longson MS, Kamauu A
Anolinx, Murray, UT, USA

PRM48
C4
COMPARATIVE LANDSCAPE ASSESSMENT OF US HEALTHCARE DATABASES FOR USE IN HEALTH ECONOMICS MODELING
Wehler EA1, Donga P1, Munakata J2
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, San Francisco, CA, USA

PRM49
C5
VALIDITY AND LIMITATIONS OF THE LONGITUDINAL PATIENT DATABASE FRANCE FOR USE IN PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMICS STUDIES
Jouaville SL, Miotti H, COFFIN G, SARFATI B, Meihoc A
Cededim Strategic Data, Boulogne-Billancourt, France

PRM50
C6
LACK OF ADHERENCE TO IMMUNOSUPPRESSIVE TREATMENT IN KIDNEY TRANSPLANT PATIENTS: COMPUTER ASSISTED QUALITATIVE DATA ANALYSIS (CAQDAS) OF AN EXPERT PANEL
Callejo D1, Rodríguez-Aguilella A1, Fernández-Ortiz L1, González E2, Toledo A2, Rebollo P1, Muduma G3
1Laser Analytica, Oviedo, Spain, 2Astellas Pharma SA, Madrid, Spain, 3Astellas Pharma Europe Ltd, Chertsey, UK

RESEARCH ON METHODS - Modeling Methods
PRM51
C7
REPLICATION OF A PUBLISHED MARKOV CHRONIC MIGRAINE COST-EFFECTIVENESS ANALYSIS MODEL FOR PURPOSES OF EARLY PHASE ADAPTATION AND EXPANSION
Smolen LJ, Klein TM, Kelton K
Medical Decision Modeling Inc., Indianapolis, IN, USA

PRM52
C8
RECONSTRUCTION OF INDIVIDUAL PATIENT DATA BASED ON PUBLISHED KAPLAN-MEIER CURVES: CASE OF REGORAFENIB FOR COLORECTAL CANCER
Ali AA, Adunlin G, Xiao H, Diaby V
Florida A & M University, Tallahassee, FL, USA

PRM53
C9
CHOICE OF DISTRIBUTIONAL ASSUMPTIONS IN META-ANALYSIS FOR THE EVALUATION OF SURROGATE ENDPOINTS
Spata E, Abrams KR, Thompson J, Bujkiewicz S
University of Leicester, Leicester, UK

PRM54
C10
UNIVERSAL CLOPIDOGREL VERSUS CYP2C19-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS
Jiang M, You J
The Chinese University of Hong Kong, Shatin, Hong Kong

PRM55
C11
JOINT ESTIMATION OF MARKOV CHAIN TRANSITION PROBABILITIES USING SURVIVAL MODELS AND CONSTRAINED OPTIMIZATION: A CASE STUDY ON DIABETES AND MORTALITY AND THEIR ASSOCIATION WITH BODY MASS INDEX, AGE, AND GENDER
Wu S1, Li J1, Carlsson NP2, Leung MY2, Colditz GA2, Chang S2
1Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO, USA, 2Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

PRM56
C12
TREE-BASED CLAIMS ALGORITHM FOR MEASURING PRE-TREATMENT QUALITY OF CARE IN MEDICARE DISABLED HEPATITIS C PATIENTS
Chirikov VV1, Shaya FT1, Onukwugha E1, Mullins CD1, dosReis S1, Howell CD2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Howard University College of Medicine, Washington, MD, USA

PRM57
C13
COST-EFFECTIVENESS EVALUATION OF GENOTYPE-GUIDED ANTIPLATELET THERAPY VERSUS UNIVERSAL NEW ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
Jiang M, You J
The Chinese University of Hong Kong, Shatin, Hong Kong

PRM58
WITHDRAWN

PRM59
C14
REAL-WORLD DATA UTILITY FOR HEALTH ECONOMIC MODELING: AN ASSESSMENT OF CURRENT DATA SOURCES
Gavaghan M1, Armstrong S2, Taggart C2, Garfield S2
1GfK, Wayland, MA, USA, 2GfK Custom Research, Wayland, MA, USA

PRM60
C15
A NEW COST-EFFECTIVENESS FRAMEWORK FOR MODELING PSORIASIS TREATMENTS
Graham C1, Mollon P2, Miles L1, McBride D1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland

PRM61
C16
NATIONAL BURDEN OF HOSPITALIZATIONS FOR NECROTIZING ENTEROCOLITIS: RESULTS FROM THE 2009 KID'S INPATINET DATABASE
Jiao X, Han X
University of Southern California, Los Angeles, CA, USA

PRM62
D1
REDUCTION OF INFLUENZA DISEASE COST WITH SUBOPTIMAL VACCINATION
Bailey N, Li Y, Wilson A
Anolinx, Murray, UT, USA

PRM63
D2
FEASIBILITY AND ACCEPTABILITY OF MINIMAL MODELING VALUE OF INFORMATION ANALYSES FOR REAL-TIME PRIORITIZATION DECISIONS WITHIN A LARGE CANCER CLINICAL TRIALS COOPERATIVE GROUP
Bennette CS1, Veenstra DL1, Basu A1, Ramsey S2, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PRM64
D3
ALTERNATIVE METHODS FOR GENERATING ARBITRARY MARGINAL DISTRIBUTIONS AND THE IMPLICATIONS FOR SIMULATION OUTCOMES
Zhuo JX
Merck, North Wales, PA, USA

PRM65
D4
AN EVALUATION OF COMPETING MODELS FOR PREDICTING CV EVENT RATES FROM LDL-C LEVELS IN SECONDARY PREVENTION
Conner C
Health Strategy, LLC, Remdond, WA, USA

PRM66
D5
THE WORLD HEALTH ORGANIZATION AND UNIVERSAL DIAGNOSTIC TESTING FOR SUSPECTED MALARIA IN CHILDREN: IS THE NEW POLICY COST-EFFECTIVE AND AFFORDABLE FOR SUB-SAHARAN AFRICA?
Phillips V
Emory University, Atlanta, GA, USA

PRM67
D6
WHOLE-DISEASE MODEL APPROACH: METHODOLOGIES AND CHALLENGES IN COMMUNICATING THE ECONOMIC BURDEN OF RARE DISEASES
Shah A, Proach J
Market Access Solutions LLC, Raritan, NJ, USA

PRM68
D7
CALIBRATING AN INTEGRATED PHARMACOECONOMIC-PHARMACOMETRIC MODEL OF COPD TREATMENT: WHAT A DIFFERENCE THE VARIANCE MAKES
Slejko JF1, Willke RJ2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Pfizer, Inc., New York, NY, USA

PRM69
D8
INFORMING UNCERTAIN MODEL PARAMETERS THROUGH MODEL CALIBRATION: HUMAN PAPILLOMAVIRUS (HPV) MODEL CASE STUDY
Minayev P1, Dasbach EJ2, Pillsbury M2
1MSD IT Global Innovation Network @ Prague, Prague, Czech Republic, 2Merck & Co. Inc., North Wales, PA, USA

PRM70
D9
PRACTICAL ISSUES IN DEVELOPING ECONOMIC MODELS FOR TARGETED TREATMENTS
Wlodarczyk J1, Kemp D1, Leadbitter S2
1John Wlodarczyk Consulting Services, New Lambton, Australia, 2AstraZeneca, North Ryde, Australia

PRM71
D10
PROGRESSION OF VISION LOSS IN PATIENTS WITH GEOGRAPHIC ATROPHY- A DISEASE MODEL
Arjunji R1, Wang F1, Gutierrez B1, Bhattacharyya A1, Alfonso R1, Williams R1, Dabbous O2
1GSK, King of Prussia, PA, USA, 2GlaxoSmithKline, King of Prussia, PA, USA

PRM72
D11
REVIEW OF METHODOLOGICAL APPROACHES TO GENERATE PROPENSITY SCORES IN MULTILEVEL DATA
Sarangpur S1, Jamotte A2, Thokagevistk K3, Sherman S1
1Creativ-Ceutical, Chicago, IL, USA, 2Creativ-Ceutical, Paris, IL, USA, 3Creativ-Ceutical, Paris, France

PRM73
D12
CONTRASTING THE RELATIVE RISK REDUCTION OF CARDIOVASCULAR EVENTS IN THE CORE DIABETES MODEL ASSOCIATED WITH SINGLE RISK FACTOR CHANGES ACROSS ALTERNATIVE RISK ENGINES: UKPDS68, UKPDS82 AND SWEDISH NATIONAL DIABETES REGISTRY EQUATIONS
Foos V1, Lamotte M2, McEwan P3
1IMS Health, Basel, Switzerland, 2IMS Health Consulting, Brussels, Belgium, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM74
D13
ASSESSING THE RELATIVE CONTRIBUTION TO CHANGES IN QUALITY-ADJUSTED LIFE EXPECTANCY ASSOCIATED WITH HBA1C, WEIGHT AND HYPOGLYCAEMIA ACROSS MULTIPLE RISK EQUATIONS WITH THE CORE DIABETES MODEL (CDM)
McEwan P1, Evans M2, Lamotte M3, Foos V4
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2University Hospital Llandough, Cardiff, UK, 3IMS Health Consulting, Brussels, Belgium, 4IMS Health, Basel, Switzerland

PRM75
D14
META-ANALYSIS FOR THE EVALUATION OF MULTIPLE SURROGATE ENDPOINTS
Bujkiewicz S, Spata E, Thompson JR, Abrams K
University of Leicester, Leicester, UK

PRM76
D15
ASSESSING THE VARIABLES AFFECTING THE COMPLETION OF A COMPLIANCE MONITORING PROGRAM (CMP) FOR NURSES UNDERGOING SUBSTANCE ABUSE TREATMENT
Pandya SA1, Moes S2, Peterson AM3
1University of the Sciences, Philadelphia, PA, USA, 2Livengrin Foundation, Inc, Bensalem, PA, USA, 3University of the Sciences in Philadelphia, Philadelphia, PA, USA

PRM77
D16
A BAYESIAN FRAMEWORK TO ESTIMATE THE COST OF CARE FOR RENAL DISEASE PATIENTS WITH AND WITHOUT A USUAL SOURCE OF CARE PROVIDER
Zanwar P1, Parthasarathy M2, Damien P3
1University of Houston Clear Lake, Houston, TX, USA, 2Saaraa Medical Solutions Pvt Ltd, Whitehouse Station, NJ, USA, 3University of Texas at Austin, Austin, TX, USA

PRM78
E1
THE USE OF BOOTSTRAP MODEL AVERAGING WHEN ESTIMATING SURVIVAL CURVES
Parker C1, Hawkins N2
1ICON Health Economics, Oxford, UK, 2London School of Hygiene & Tropical Medicine, London, UK

RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM79
E2
DEVELOPMENT AND VALIDATION OF THE HEMOPHILIA-SPECIFIC BURDEN SCALE FOR CAREGIVERS OF CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)
von Mackensen S1, Wisniewski T2, Urgo J3, Boggio L3
1University Medical Center, Hamburg, Germany, 2NOVO Nordisk, Plainsboro, NJ, USA, 3RUSH University Medical Centre, Chicago, IL, USA

PRM80
WITHDRAWN

PRM81
E3
USING THE CLINICAL SUMMARY SCORE FROM THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE AS AN ENDPOINT IN CLINICAL TRIALS: PSYCHOMETRIC SUPPORT
Gwaltney C1, Tiplady B1, Deschaseaux C2
1ERT, Pittsburgh, PA, USA, 2Novartis Pharma AG, Basel, Switzerland

PRM82
E4
VALIDATION AND U.S. POPULATION NORMS OF HEALTH-RELATED PRODUCTIVITY QUESTIONNAIRE
Tundia N1, Hass S2, Fuldeore M1, Wang LL3, Cavanaugh T3, Boone J3, Heaton P3
1AbbVie Inc., North Chicago, IL, USA, 2Genzyme, Cambridge, IL, USA, 3University of Cincinnati, Cincinnati, OH, USA

PRM83
E5
MEASURING UPPER LIMB FUNCTION IN MULTIPLE SCLEROSIS: ENHANCING THE ABILHAND'S PERFORMANCE
Cano S1, Cleanthous S2, Marquis P3, Hobart J4, Naoshy S5, Mikol D5, Petrillo J5, Steiner D5, Chen Y5, Watson C5
1Modus Outcomes, Stotfold, UK, 2Modus Outcomes LLC, London, UK, 3Modus Outcomes, Newton, MA, USA, 4Plymouth University, Plymouth, Devon, UK, 5Biogen Idec, Cambridge, MA, USA

PRM84
E6
VALIDATION OF THE DEPRESSION AND FAMILY FUNCTIONING SCALE (DFFS)
Francois C1, Danchenko N2, Williams V3, Nelsen L3, Williams NJ3, Yarr S4, DiBenedetti DB3, Lancon C5
1Lundbeck LLC, Deerfield, IL, USA, 2Lundbeck S.A.S. Paris Fr, EU, Paris, France, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4The Pavilion, Manchester, UK, 5Hospital Sainte-Marguerite, Marseille, France

PRM85
E7
DOES DIFFERENTIAL FRAMING OF OPT-OUT ALTERNATIVES IN DISCRETE CHOICE EXPERIMENTS (DCES) MATTER? COMPARISON OF RANDOM UTILITY MAXIMIZATION (RUM) AND RANDOM REGRET MINIMIZATION (RRM) MODELS
Chaugule S1, Hay JW1, Young G2, Martin OA3, Drabo EF1
1University of Southern California, Los Angeles, CA, USA, 2Children's Hospital Los Angeles, Los Angeles, CA, USA, 3Barcelona GSE, Barcelona, Spain

PRM86
WITHDRAWN

PRM87
E8
THE INFLUENCE OF PAIN MANAGEMENT TREATMENT ATTRIBUTES ON CLINICAL DECISION MAKING IN POSTOPERATIVE PAIN MANAGEMENT
Abraham J1, Lozano-Ortega G2, Ogden K3, Jones J4
1The Medicines Company, Waltham, MA, USA, 2ICON, Vancouver, BC, Canada, 3ICON, San Francisco, CA, USA, 4The Medicines Company, Parsippany, NJ, USA

PRM88
E9
DEVELOPMENT OF THE HYPERPHAGIA QUESTIONNAIRE FOR USE IN PRADER-WILLI SYNDROME CLINICAL TRIALS
Fehnel SE1, Brown TM1, Nelson L1, Chen A2, Kim DD2, Roof E3, Dykens EM3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Zafgen, Inc., Boston, MA, USA, 3Vanderbilt University, Nashville, TN, USA

PRM89
E10
PATIENTS' EXPERIENCES WITH MYCOSIS FUNGOIDES/SÉZARY SYNDROME - CUTANEOUS T-CELL LYMPHOMA (MF/SS-CTCL): EVIDENCE FROM QUALITATIVE RESEARCH OF A PATIENT REPORTED OUTCOME (PRO) MEASURE DEVELOPED ON AN ONLINE RESEARCH PLATFORM
Towner A1, Raja P1, Braverman J1, Harrington M1, Simacek K1, Nagao M2, Sepassi M2
1PatientsLikeMe, Cambridge, MA, USA, 2Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA

PRM90
E11
CONTENT VALIDITY OF A PATIENT-REPORTED OUTCOME INSTRUMENT FOR PANCREATIC CANCER
Turner-Bowker DM1, Paty J2, Celeste Elash CA3, Hare T4, Leopold L4, Cline J3, Ascoytia C5
1Quintiles (work conducted while at ERT, Pittsburgh, PA), Cambridge, MA, USA, 2Quintiles, Hawthorne, NY, USA, 3ERT, Pittsburgh, PA, USA, 4Incyte Corporation, Wilmington, DE, USA, 5Health Research Associates, Mountlake Terrace, WA, USA

PRM91
E12
DEPRESSION AND QUALITY OF LIFE AMONG INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN NORTH INDIA
Negi H1, Raval A2
1Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, 2West Virginia University, Morgantown, WV, USA

PRM92
E13
MEASURING THE SYMPTOMS AND IMPACTS OF ENDOMETRIOSIS: PSYCHOMETRIC VALIDATION OF THE ENDOMETRIOSIS SYMPTOM DIARY AND ENDOMETRIOSIS IMPACT SCALE
Gater A1, Moore A2, Coon CD3, Chen WH4, Wichmann K5, Hartisch C5, Filonenko A5, Seitz C5, Gerlinger C5
1Adelphi Values, Bollington, Cheshire, UK, 2Adelphi Values Ltd, Bollington, Cheshire, UK, 3Adelphi Values, Boston, MA, USA, 4RTI Health Solutions, North Potomac, MD, USA, 5Bayer Pharma AG, Berlin, Germany

PRM93
E14
WHAT TYPE OF RESPONSE SCALE IS THE MOST RESPONSIVE? A COMPREHENSIVE REVIEW OF RESPONSE SCALE OPTIONS FOR PATIENT-REPORTED OUTCOME MEASURES
Rudell K1, Vernon MK2, Gries KS3, Safikhani S4, DeLozier AM5, McQuarrie K6, Norquist JM7, Coons SJ8
1Pfizer Inc, Tadworth, UK, 2Evidera, London, UK, 3Evidera, Seattle, WA, USA, 4Evidera, Bethesda, MA, USA, 5Lilly, Indianapolis, IN, USA, 6Janssen Global Services, LLC, Raritan, NJ, USA, 7Merck & Co Whitehouse Station, Whitehouse Station, NJ, USA, 8Critical Path Institute, Tucson, AZ, USA

PRM94
E15
PSYCHOMETRIC VALIDATION OF THE FATIGUE SYMPTOMS AND IMPACTS QUESTIONNAIRE–RELAPSING MULTIPLE SCLEROSIS (FSIQ-RMS™)
Hudgens S1, Schüler R2, Hunsche E2, Leist T3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 3Thomas Jefferson University Hospital, Philadelphia, PA, USA

PRM95
E16
FEASIBILITY OF USING THE SF-36 HEALTH SURVEY TO SCREEN FOR RISK OF MAJOR DEPRESSIVE DISORDER
Bell JA1, DiBonaventura MD2, Witt EA3, Ben-Joseph R1, Reeve BB4
1Purdue Pharma L.P., Stamford, CT, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Princeton, NJ, USA, 4University of North Carolina, Chapel Hill, NC, USA

PRM96
F1
WITHDRAWN

PRM97
F2
ELICITING PATIENT TREATMENT PREFERENCES: DEVELOPMENT OF A METHODOLOGICAL FRAMEWORK FOR ATTRIBUTE IDENTIFICATION AND VALIDATION FOR DISCRETE CHOICE EXPERIMENTS
Camelo Castillo W1, Ross MM1, Fitz-Randolph M2, dosReis S1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2PatientsLikeMe, Cambridge, MA, USA

PRM98
F3
PHARMACISTS-LED INTERVENTIONS TO IMPROVE HEALTH-RELATED QUALITY OF LIFE OF PULMONARY TUBERCULOSIS PATIENTS IN PAKISTAN: AN INSIGHT FROM A RANDOMIZED CONTROLLED NON-CLINICAL TRIAL
Iqbal MS1, Iqbal MZ2, Iqbal MW3, Nasir S4, Bahari MB5
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 3Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 4Nishtar Hospital, Multan, Pakistan, 5Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia

PRM99
F4
DEVELOPING SF-6D-V2: EXAMINING THE DIMENSIONALITY OF THE SF-36 USING LARGE MULTINATIONAL DATASETS
Mulhern B1, Brazier J2, Bjorner JB3
1University of Technology Sydney, Sydney, Australia, 2University of Sheffield, Sheffield, UK, 3University of Copenhagen, Copenhagen, Denmark

PRM100
F5
DEVELOPMENT AND VALIDATION OF THE PROMIS NETWORK TO EVALUATE PATIENT-REPORTED HEALTH STATUS ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION
Desai NS1, Vuong NN2, Bozorgui S3, Goddu S3, Broderick KC1, Kuo JK4, Shah DN4, Garey KW4
1Cubist Pharmaceuticals, Lexington, MA, USA, 2University of Houston College of Pharmacy, Houston, TX, USA, 3St. Luke’s Episcopal Hospital, Houston, TX, USA, 4Department of Clinical Sciences and Administration University of Houston College of Pharmacy, Houston, TX, USA

PRM101
F6
VALIDATION AND VALUATION OF THE PREFERENCE-BASED HEALTHINDEX USING EQ-5D-5L IN THE HONG KONG POPULATION
Wong EL1, Yeoh EK1, Slaap B2, Tam WW3, Cheung AW1, Wong AY1, Chan DC1
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The EuroQol Group Association, Rotterdam, The Netherlands, 3National University of Singapore, Singapore, Singapore

PRM102
F7
USABILITY TESTING OF THE WEB-BASED VERSIONS OF THE STANDARDISED ASTHMA QUALITY OF LIFE QUESTIONNAIRE FOR 12 YEARS AND OLDER (AQLQ(S)+12) AND THE ASTHMA CONTROL QUESTIONNAIRE (ACQ-6)
Juniper EF1, Lambe J2, Thomas M3, Arden-Close E3, Grataloup G2
1McMaster University, Hamilton, ON, Canada, 2Mapi, Lyon, France, 3University of Southampton, Southampton, UK

PRM103
F8
DEVELOPMENT AND CONTENT VALIDITY OF A PEDIATRIC FUNCTIONAL CONSTIPATION DAILY DIARY
Turner-Bowker DM1, Lindner E2, Mareya S2, Losch-Beridon T2, Elash CA3, Paty J4, Keithly S5, Ascoytia C5
1Quintiles (work conducted while at ERT, Pittsburgh, PA), Cambridge, MA, USA, 2Sucampo Pharma Americas LLC, Bethesda, MD, USA, 3ERT, Pittsburgh, PA, USA, 4Quintiles, Hawthorne, NY, USA, 5Health Research Associates, Mountlake Terrace, WA, USA

PRM104
F9
WHEN THE LITERAL MEANING JUST WON'T DO - CULTURAL ADAPTATION ISSUES RESOLVED DURING THE LINGUISTIC VALIDATION OF A BEHAVIOURAL SCALE
Williams H, Oke L, Scharf L, Anderson H, Gergovich B
ICON Plc, Oxford, UK

PRM105
F10
MEASUREMENT EQUIVALENCE AND PATIENT PREFERENCE FOR THE SF-36V2 ON A HANDHELD DEVICE AND SMARTPHONE APP
Khurana L1, White MK2, Bjorner JB3, Gary ST1, Vazquez V1, Otero A1, Dallabrida S1
1PHT Corporation, Boston, MA, USA, 2Optum PatientInsights, Lincoln, RI, USA, 3University of Copenhagen, Copenhagen, Denmark

PRM106
F11
DEVELOPMENT AND VALIDATION OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR (ACEI) INDUCED ANGIOEDEMA INVESTIGATOR RATING SCALE AND PROPOSED DISCHARGE CRITERIA
Bonner N1, Kimura A2, Panter C1, Sinert R3, Moellman JJ4, Bernstein JA4
1Adelphi Values Ltd, Bollington, UK, 2Shire HGT, Lexington, MA, USA, 3SUNY - Downstate Medical Centre, Brooklyn, NY, USA, 4University of Cincinnati, Cincinnati, OH, USA

PRM107
F12
DEVELOPMENT OF A DISEASE MODEL FOR SPORADIC INCLUSION BODY MYOSITIS (SIBM)
Gnanasakthy A1, DeMuro C1, Lewis S1, Tseng B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals, Cambridge, MA, USA

PRM108
F13
HEALTH-RELATED QUALITY OF LIFE AMONG ESRF PATIENTS IN PAKISTAN: A CROSS-SECTIONAL APPROACH USING WHOQOL-BREF
Iqbal MZ1, Iqbal MS2, Iqbal MW3, Bahari MB4, Nasir S5
1Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 2Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 3Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 4Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 5Nishtar Hospital, Multan, Pakistan

PRM109
F14
CHALLENGES IN TRANSLATING THE CONNERS 3RD EDITION–PARENT INTO 12 LANGUAGES
Verne A, Bailly C, Rouillat C
Mapi, Lyon, France

PRM110
F15
THE IMPORTANCE OF ANCHOR BASED MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) TO HEALTH TECHNOLOGY ASSESSMENT OF ESTABLISHED INTRANASAL ALLERGIC RHINITIS TREATMENTS
Brixner D1, Meltzer EO2, Morland K3, Carroll CA3, Lipworth BJ4
1University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 2Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA, 3Xcenda, Palm Harbor, FL, USA, 4Ninewells Hospital and School of Medicine, Dundee, UK

PRM111
F16
CAN'T WE JUST USE THIS PORTUGUESE TRANSLATION IN BRAZIL? ANALYSING WHY THERE IS MORE TO COUNTRY-SPECIFIC PROS THAN TICKING/CHECKING BOXES
Simpson H, Bellhouse G, Neal R, Two R
PharmaQuest Ltd., Bloxham, UK

PRM112
G1
VALIDATION OF A VITALITY QUOTIENT TO MEASURE THE EFFECT OF FOOD SUPPLEMENTS ON FATIGUE IN HEALTHY SUBJECTS
Allaert F1, Courau S2, Forestier A2
1Medical evaluation Chair ESC Dijon, Dijon, France, 2Merck CH, Dijon, France

PRM113
G2
CHALLENGES FACED DURING LINGUISTIC VALIDATION FOR SOUTH AFRICA
Towns L, Williams H, Anderson H, Gergovich B
ICON Plc, Oxford, UK

PRM114
G3
RECOMMENDATIONS FOR THE LINGUISTIC VALIDATION OF PEDIATRIC CLINICAL OUTCOMES ASSESSMENTS
Gawlicki M1, Brandt B1, McKown S1, Talbert M2
1Corporate Translations Inc, East Hartford, CT, USA, 2Corporate Translations Inc, Chicago, IL, USA

PRM115
G4
USE OF WORK PRODUCTIVITY ENDPOINTS IN CLINICAL STUDIES: A REVIEW BY DISEASE STATE AND MEASUREMENT TYPE
Popelar B, Walters T, Zagadailov EA, Houle C, Duhig A
Xcenda, Palm Harbor, FL, USA

PRM116
G5
REVIEW OF CAREGIVER BURDEN SCALES FOR PATIENTS WITH VISUAL IMPAIREMENT IN JAPAN
Narimatsu A, Ishii K, Adachi K
Bayer Yakuhin Ltd., Tokyo, Japan

PRM117
G6
DEVELOPMENT OF ELECTRONIC DIARY IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
Gilchrist K, Vallow S
GlaxoSmithKline, King of Prussia, PA, USA

PRM118
G7
ASSESSMENT OF TREATMENT ADHERENCE AND QUALITY OF LIFE IN DIABETIC PATIENTS TREATED WITH INSULIN IN TWO COLOMBIAN CITIES
Medina Morales DA, Machado Alba JE, Echeverry-Cataño LF, Londoño-Builes MJ
Universidad Tecnológica de Pereira, Pereira, Colombia

PRM119
G8
IMPORTANCE OF THE CONCEPTUAL DEFINITION OF PRO MEASURES: A CASE STUDY WITH THE LINGUISTIC VALIDATION OF THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE (IBS-QOL) INSTRUMENT IN 17 ASIATIC LANGUAGES
Lambe J1, Patrick DL2, Toraubully N1, Skerritt B3, Acquadro C4
1Mapi, Lyon, France, 2University of Washington, Seattle, WA, USA, 3ICON, Dublin, Ireland, 4Mapi Research Trust, Lyon, France

RESEARCH ON METHODS - Statistical Methods
PRM120
G9
EVALUATION OF MATCHING-ADJUSTED INDIRECT COMPARISON IMPLEMENTED BY A RESAMPLING METHOD
Wang J1, Odom D2, Chirila C1, Zheng Q1
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PRM121
G10
A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF NETWORK META-ANALYSES
Chambers J1, Naci H2, Wouters O2, Pyo J1, Gunjal S3, Kennedy I4, Hoey M4, Winn A5, Neumann PJ6
1Tufts Medical Center, Boston, MA, USA, 2London School of Economics, London, UK, 3Precision Health Economics, Austin, TX, USA, 4Royal Victoria Hospital, Belfast, UK, 5The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 6Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PRM122
G11
APPLICATION OF DIFFERENCE-IN-DIFFERENCE METHODOLOGY IN COMPARATIVE EFFECTIVENESS RESEARCH WITH UNBALANCED GROUPS
Li Y1, Zhou H2, Ko JJ1, Hawker K1, Nazareth T1, Arcona S1, Sasane R1
1Novartis Pharmaceuticals, East Hanover, NJ, USA, 2KmK Consulting Inc. for Novartis Pharmceuticals, Florham Park, NJ, USA

PRM123
G12
LOW-MOLECULAR-WEIGHT HEPARIN TREATMENT OF DEEP-VEIN THROMBOSIS: A NETWORK META-ANALYSIS
Diaz JP1, Soto Molina H2, Marquez M3, Escobar Juárez Y2
1Universidad Nacional Autonoma de Mexico, México D.F., Mexico, 2HS Estudios Farmacoeconómicos, Mexico City, Mexico, 3Universidad Autonoma Metropolitana, México D.F., Mexico

PRM124
G13
ALTERNATIVE WEIGHTING APPROACHES FOR MATCHING ADJUSTED INDIRECT COMPARISONS (MAIC)
Belger M1, Brnabic A2, Kadziola Z3, Petto H3, Faries D4
1Eli Lilly and Company (Lilly UK), Surrey, UK, 2Eli Lilly, Sydney, Australia, 3Eli Lilly Regional Operations GmbH, Vienna, Austria, 4Eli Lilly, Indianapolis, IN, USA

PRM125
G14
PSYCHOTROPIC PHARMACOTHERAPY ASSOCIATED WITH QT PROLONGATION AMONG VETERANS WITH POSTTRAUMATIC STRESS DISORDER
Stock EM1, Zeber JE1, McNeal CJ2, Banchs JE2, Copeland LA1
1Center for Applied Health Research - Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA, 2Baylor Scott & White Health, Temple, TX, USA

PRM126
G15
ENSURING APPLICABILITY OF REAL WORLD EVIDENCE TO INDIVIDUAL PATIENT DECISION MAKING
Numapau NO1, Hess LM1, Brnabic A1, Cuyun Carter G1, Araujo AB2, Robinson R1, Swindle R1
1Eli Lilly, Indianapolis, IN, USA, 2ELI Lilly, Indianpolis, IN, USA

PRM127
G16
EMPIRICAL ESTIMATION OF STATISTICAL POWER AND MINIMUM NUMBER OF STUDIES NEEDED FOR A NETWORK META-ANALYSIS
Parks DC1, Lee K1, Dabbous O2, Lin X1, Cockle S3, Stanford R4, Alfonso-Cristancho R5
1GSK, Phoenixville, PA, USA, 2GlaxoSmithKline, King of Prussia, PA, USA, 3GSK, London, UK, 4GSK, Research Triangle Park, NC, USA, 5GlaxoSmithKline (GSK), King of Prussia, PA, USA

PRM128
G17
ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008
Balbinotto G1, Wiest R2, Jacinto P3
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil, 3puc/rs, PORTO ALEGRE, Brazil

PRM129
G18
CLUSTER ANALYSIS OF HEALTHCARE COSTS PATTERNS IN END STAGE RENAL DISEASE PATIENTS WHO INITIATED HEMODIALYSIS
Liao M1, Li Y2, Kianifard F2, Obi E3, Arcona S2
1KMK Consulting Inc., Florham Park, NJ, USA, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3Rutgers University, Piscataway, NJ, USA

PRM130
G19
INCLUSION OF MULTIPLE STUDIES IN MATCHING ADJUSTED INDIRECT COMPARISONS (MAIC)
Belger M1, Brnabic A2, Kadziola Z3, Petto H3, Faries D4
1Eli Lilly and Company (Lilly UK), Surrey, UK, 2Eli Lilly, Sydney, Australia, 3Eli Lilly Regional Operations GmbH, Vienna, Austria, 4Eli Lilly, Indianapolis, IN, USA

PRM131
G20
CLASSIFICATION TREE ANALYSIS OF THE LIKELIHOOD OF CLOPIDOGREL TREATMENT IN A COHORT OF PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE
Reed Chase M1, Friedman H2, Navaratnam P2, Heithoff K1, Simpson Jr. RJ3
1Merck & Co., Kenilworth, NJ, USA, 2DataMed Solutions LLC, New York City, NY, USA, 3University of North Carolina, Chapel Hill, NC, USA

RESEARCH ON METHODS - Study Design
PRM132
G21
HOW MANY SUBJECTS ARE ENOUGH FOR SYMPTOM-FOCUSED CONCEPT ELICITATION STUDIES? A RETROSPECTIVE ANALYSIS OF SATURATION ACROSS TWENTY-SIX STUDIES
Lamoureux RE, Shields A, Stokes J, Yaworsky A, Galipeau N
Adelphi Values USA, Boston, MA, USA

PRM133
H1
EXPLORING THE REAL WORLD SETTING OF CHRONIC IDIOPATHIC URTICARIA AND PHYSICIAN ATTITUDES TOWARDS IT IN THE US
Gabriel S1, Herrera V2, Hoskin B3, Anderson P4, Karagiannis T5
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3Adelphi Real World, Macclesfield, MA, USA, 4Adelphi Real World, Macclesfield, UK, 5Jefferson School of Population Health for Novartis Pharmaceuticals, East Hanover, NJ, USA

PRM134
H2
HTA DECISIONS AND COMPARATOR CHANGES OVER TIME IN RHEUMATOID ARTHRITIS
Sliman RC, Rubinstein ER, Versoza L, Lurie BF, Westbrook L, Sanchez DP, Rubinstein JL, Ho Y
Context Matters, Inc., New York, NY, USA

PRM135
H3
RESPONSE RATES IN DIRECT-TO-PATIENT SURVEYS
Goolsby Hunter A, Brenneman S
Optum, Eden Prairie, MN, USA

PRM136
H4
PHARMACOECONOMICS EDUCATION IN WHO EASTERN MEDITERRANEAN REGION
Al-Efan QM1, Al-Emam S1, Mukattash TL1, Mhaidat NM1, Al-Abbadi I2, Rascati K3
1Jordan University of Science & Technology, Irbid, Jordan, 2University of Jordan, Amman, Jordan, 3University of Texas at Austin, Austin, TX, USA

PRM137
H5
AN INVESTIGATION INTO RHEUMATOID ARTHRITIS COMPARATORS AND SUBPOPULATIONS
Lurie BF, Rubinstein ER, Versoza L, Sliman RC, Westbrook L, Sanchez DP, Rubinstein JL, Ho Y
Context Matters, New York, NY, USA

PRM138
H6
A PRAGMATIC LITERATURE REVIEW OF NETWORK META-ANALYSES OF DISEASE-MODIFYING DRUGS IN THE TREATMENT OF MULTIPLE SCLEROSIS
Phillips AL1, Beckerman R2, Smith NJ2, Locklear JC1, Jiang Y2, Solon C3
1EMD Serono, Inc., Rockland, MA, USA, 2CBPartners, New York, NY, USA, 3CBPartners, San Francisco, CA, USA

PRM139
H7
KNOWLEDGE AND AWARENESS OF ORAL CANCER IN GUNTUR AREA,SOUTH INDIA
Vasireddy KS
Chalapathi Institute Of Pharmaceutical Sciences, Guntur, India

RESEARCH ON METHODS - Conceptual Papers
PRM140
H8
EXPLORING HETEROGENEITY IN ATTRIBUTE PROCESSING STRATEGIES: USE OF HYBRID RANDOM UTILITY MAXIMIZATION-RANDOM REGRET MINIMIZATION (RUM-RRM) MODELS IN A DISCRETE CHOICE EXPERIMENT (DCE)
Chaugule S1, Hay JW1, Young G2
1University of Southern California, Los Angeles, CA, USA, 2Children's Hospital Los Angeles, Los Angeles, CA, USA

PRM141
H9
AN ANALYTICAL CRITERION FOR JUDGING THE EXTENDED DOMINANCY OF A NEW TECHNOLOGY COMPARED TO THE STANDARD OF CARE AND PLACEBO CONTROL
Kamae I1, Sugimoto T1, Yamabe K2
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2The University of Tokyo, Tokyo, Japan

PRM142
H10
THE EXPANDED NUMBER NEEDED TO TREAT: APPLYING THE CONCEPT OF NNT TO CONTINUOUS HEALTH ECONOMIC OUTCOMES
O'Day K, Campbell DJ
Xcenda, Palm Harbor, FL, USA

PRM143
H11
IMPORTANT STATISTICAL CONSIDERATIONS FOR DEVELOPING EQUATIONS FOR DISEASE SIMULATORS
Ishak KJ1, Kansal A2, Krotneva M3, Tarko L4, Tafazzoli A2
1Evidera, Montreal, QC, Canada, 2Evidera, Bethesda, MD, USA, 3Evidera, St-Laurent, QC, Canada, 4Evidera, Lexington, MA, USA

PRM144
H12
PACE CONTINUOUS INNOVATION INDICATORS—A NOVEL TOOL TO MEASURE PROGRESS IN CANCER TREATMENTS
Paddock S1, Brum LM1, Sorrow K1, Thomas S1, Spence S1, Maulbecker-Armstrong C2, Goodman C3, Peake M4, McVie G5, Ramers-Verhoeven C6, Geipel G7, Li R1
1Rose Li and Associates, Inc., Bethesda, MD, USA, 2German Ministry of Health, Wiesbaden, Germany, 3The Lewin Group, Falls Church, VA, USA, 4University of Leicester, Leicester, UK, 5European Institute of Oncology, Milan, Italy, 6Eli Lilly and Company, Houten, The Netherlands, 7Eli Lilly and Company, Indianapolis, IN, USA

PRM145
H13
REVIEWING CLINICAL OUTCOME ASSESSMENT USAGE IN CLINICAL TRIALS: INTRODUCING THE COLA METHODOLOGY
Trigg A, Kitchen H, Willgoss TG, Meysner S, Humphrey L
Abacus International, Manchester, UK

PRM146
H14
ADVANCING METHODS OF HTA: OPTIMISING MONITORING TESTS TO MEET VALUE TARGETS
McCabe C, Paulden M, Akude P
University of Alberta, Edmonton, AB, Canada

PRM147
H15
THE PROCESSES FOR A COMMON QUALITY ASSURANCE APPROACH TO MULTI-CENTRE CLINICAL TRIALS – THE MARS EXCITE EXPERIENCE
Aziziyeh A1, Easty T2, Khayat Z1, Kozlowski N3, Bowen J4, Rac V5, Garritty C6, Levin L1
1MaRS Discovery District, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Applied Health Research Centre, Toronto, ON, Canada, 4St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Ottawa Hospital Research Institute, Ottawa, ON, Canada

PRM148
H16
INNOVATION IN THE DEVELOPMENT AND VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COA): AN EXPLORATION OF PATIENT-CENETERED CREATIVE METHODOLOGIES
Meysner S, Willgoss TG, Kitchen H, Trigg A, Humphrey L
Abacus International, Manchester, UK

PRM149
H17
COMPARING THE ADOPTION OF EPRO IN CLINICAL RESEARCH TO EMR IN CLINICAL PRACTICE – WHY CLINICAL PRACTICE IS AHEAD OF RESEARCH WITH TECHNOLOGY USE
Ross J, Holzbaur E, Rothrock T, Wade M
Almac Clinical Technologies, Souderton, PA, USA

PRM150
H18
METHODS AND CONTEXT FOR THE PRODUCTION OF RAPID REVIEWS
Kato EU1, Hartling L2, Guise J3
1AHRQ, Rockville, MD, USA, 2University of Alberta, Edmonton, AB, Canada, 3Oregon Health & Science University, Portland, OR, USA

PRM151
H19
RESOURCE MODELLING: THE MISSING PIECE OF THE HTA JIGSAW?
Thokala P1, Dixon S1, Jahn B2
1University of Sheffield, Sheffield, UK, 2University for Health Sciences, Medical Informatics and Technology (UMIT),, Tirol, Austria

PRM152
H20
DATA CLEANING PAPER PATIENT REPORTED OUTCOME (PRO) DATA VERSUS ELECTRONIC PATIENT REPORTED OUTCOME (EPRO) DATA
Ross J, Holzbaur E, Wade M, Rothrock T
Almac Clinical Technologies, Souderton, PA, USA

PRM153
H21
RETHINKING COST-EFFECTIVENESS IN THE ERA OF ZERO HEALTHCARE SPENDING GROWTH
Arbel R1, Greenberg D2
1Sapir College, Sderot, Israel, 2Ben-Gurion University of the Negev, Beer-Sheva, Israel

PRM154
I1
THE ELECTRONIC AGE: INTEGRATING EPRO/ECOA TO REDUCE PATIENT, SITE, AND STUDY TEAM BURDEN
Holzbaur E, Ross J, Wade M, Rothrock T
Almac Clinical Technologies, Souderton, PA, USA

PRM155
I2
ADOPTING SOFTWARE ENGINEERING BEST PRACTICES IN THE FIELD OF PHARMACOECONOMICS CAN INCREASE THE TRANSPARENCY OF AND CONFIDENCE IN OUR HEALTH ECONOMIC MODELS
Dasbach EJ1, Kruger M2, Prabhu V1
1Merck & Co. Inc., North Wales, PA, USA, 2Merck & Co., Inc., Boston, MA, USA

PRM156
I3
DIRECTLY ELICITING PERSONAL UTILITY FUNCTIONS: A NEW WAY TO VALUE HEALTH-RELATED QUALITY OF LIFE
Shah K1, Devlin N1, Mulhern B2, van Hout B2
1Office of Health Economics, London, UK, 2University of Sheffield, Sheffield, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.